Zoldria
Zoldria (Zoledronic Acid 4 mg/100 mL IV) — Sun Pharma bisphosphonate for cancer-related bone metastases, hypercalcaemia of malignancy, and osteoporosis. Hospital-administered IV infusion.
✓ Medisinsk vurdert av Morgan Ellis — Farmasøytisk forsker · 8 års erfaring · Sist gjennomgått: mai 2026
Kort svar
Zoldria — Zoledronic Acid 4 mg/100 mL (Sun Pharma). Bisphosphonate — for cancer-related bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia, Paget’s disease, and severe osteoporosis. IV infusion under specialist supervision.
Hva du får med MedsBase:
- WHO-GMP-sertifisert produsent
- Diskré emballasje i vanlig konvolutt
- Verdensomspennende levering
- Vurdert av over 1 400 kunder (les anmeldelser)
📦 Reshipment Assurance: hvis din ordre ikke har kommet frem 20 virkedager etter forsendelse, sender vi den på nytt uten ekstra kostnad. Les policyen.
Hvorfor bestille fra MedsBase
Zoldria ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All bisphosphonates carry ONJ risk — higher with IV agents (zoledronic acid, ibandronate IV) and longer cumulative therapy. Pre-treatment dental review is mandatory; complete invasive dentistry before starting. Avoid invasive dental procedures during therapy if possible. Notify dentist about bisphosphonate use lifelong (effects persist years after stopping).
Bisphosphonates are renally cleared. Adequate hydration before/during IV administration. Monitor renal function and serum calcium. Hypocalcaemia is common; supplement with calcium + vitamin D throughout therapy. Avoid in CrCl <30 (oral) or <35 (IV).
Vanlige spørsmål
When is this used?
Bone metastases (myeloma, breast, prostate, lung), tumour-induced hypercalcaemia (zoledronic acid IV is fastest), Paget’s disease, and severe osteoporosis (especially adjuvant during AI therapy in breast cancer).
IV vs oral?
IV (zoledronic acid 4 mg q3-4 weekly for cancer; q12 monthly for osteoporosis; ibandronate 6 mg q3-4 weekly): more potent, fewer doses, no GI absorption issues. Oral (ibandronate 150 mg monthly): convenient, no IV access needed, but oesophagitis risk and absorption issues.
ONJ — how worried should I be?
ONJ is rare but cumulative. Risk factors: invasive dental procedures (extraction, implants), poor dental hygiene, smoking, diabetes, glucocorticoid use. Pre-treatment dental review and ongoing oral hygiene minimise risk. Discuss any planned dental work with your oncology team.
Calcium and vitamin D?
Mandatory throughout bisphosphonate therapy: calcium 1000-1500 mg/day plus vitamin D 800-1000 IU/day. Reduces hypocalcaemia risk and improves bone density.
Legemiddelinteraksjoner?
Calcium, magnesium, aluminium-containing antacids, iron, multivitamins reduce absorption (oral) — separate by ≥30 minutes. NSAIDs + bisphosphonates: increased GI risk. Aminoglycosides + bisphosphonates: increased nephrotoxicity.
Graviditet?
Long half-life in bone (years to decades). Generally avoided in pre-menopausal women without effective contraception. Limited human pregnancy data.
Hva om jeg glemmer en dose?
Oral monthly: take next morning if remembered the same week; if missed entirely, return to the original schedule next month. IV: scheduled by specialist; reschedule with oncology team.
Atypical femoral fracture?
Rare class effect after long-term use (typically >5 years osteoporosis use). Drug holiday at 3-5 years considered in osteoporosis. Cancer use typically continues based on disease state.
Acute phase reaction?
Common after first IV bisphosphonate dose: fever, myalgia, arthralgia, fatigue 1-3 days post-infusion. Usually mild, paracetamol-responsive, less severe with subsequent doses.
Stopping?
Specialist-determined based on disease, response, toxicity. Bisphosphonate effect on bone persists for years after stopping due to bone deposition.
Other Cancer & Bone-Health Medications
- Zoldria — zoledronic acid IV — for bone mets and hypercalcaemia
- Bandrone — ibandronate — alternative bisphosphonate
- Idrofos — ibandronate 150 mg monthly oral
- Osteofos — alendronate weekly — for osteoporosis
- Calcirol — vitamin D3 60,000 IU sachet — for adequacy
More options in Anti Cancer Medication
Rangert etter nylig bestillingsvolum på MedsBase — hva andre kunder i denne kategorien velger.
| Styrke | 4 mg |
|---|---|
| Antall | 1 Injection/s, 3 Injection/s, 6 Injection/s |
| Farmasøytisk form | Injection/s |
| Produsent | Cipla Inc |
| Behandling | Osteoporosis |
| Generisk merke | Zoledronic Acid |
Zoldria
Spørsmål og svar
Zoldria
Relaterte produkter
Anmeldelser
Det er ingen anmeldelser ennå